evipedia.ai
← Back

Piceatannol for Health & Longevity

Evidence Review created on 09/24/2026 using AI4L / Opus 5.5

Also known as: 3,3’,4,5’-tetrahydroxystilbene, Astringenin, PIC

Motivation

Piceatannol is a plant compound that is a close chemical relative of resveratrol, the red-wine molecule that drew wide attention for its effects on aging pathways in animals. It occurs in passion fruit seeds, grapes, blueberries and white tea, and the body also makes small amounts of it from resveratrol. Interest comes from its apparent ability to switch on cellular stress-defense and energy-sensing programs linked to healthy aging, while holding up better in the body than resveratrol in animal studies.

Most of the research consists of cell and animal studies, including work in which it lengthens the lives of worms and reduces signs of aging cells in mice. Human research is limited to a few short, small trials, most funded by the Japanese company that makes a passion fruit seed extract, reporting effects on skin moisture and blood glucose control in selected groups.

This review examines what the human, animal and laboratory evidence shows about the benefits, risks, dosing and monitoring of piceatannol for health-focused adults considering it within a longevity strategy, and where the evidence has gaps.

Benefits - Risks - Protocol - Conclusion

The following sources give an in-depth overview of piceatannol’s biology, metabolic potential, safety data and longevity framing.

No piceatannol content was found from Rhonda Patrick (foundmyfitness.com), Andrew Huberman (hubermanlab.com), Chris Kresser (chriskresser.com) or Lifespan.io; web searches and on-site searches of each platform returned no relevant results.

Grokipedia

Piceatannol

An AI-generated encyclopedia entry covering piceatannol’s chemistry, food sources, formation from resveratrol and preclinical activities; useful for orientation, though it notes human clinical data remain limited.

Examine

Piceatannol benefits, dosage, and side effects

Examine’s evidence page describes piceatannol as a resveratrol-like stilbene present in limited amounts in foods and concludes the evidence is insufficient to call it better than resveratrol.

ConsumerLab

No ConsumerLab article on piceatannol exists; a direct search of consumerlab.com returned no results, and ConsumerLab has not published product testing of piceatannol supplements.

Systematic Reviews

No systematic reviews or meta-analyses for Piceatannol were found on PubMed as of September 24, 2026.

As a result, neither the claimed benefits nor the principal risks of piceatannol are represented by any systematic review or meta-analysis.

Mechanism of Action

Piceatannol is resveratrol with one extra hydroxyl group (an oxygen-hydrogen unit), forming a catechol ring (two neighboring hydroxyl groups) that makes it a stronger free-radical scavenger and a more reactive signaling molecule. Proposed longevity-relevant actions, mostly from cell and animal work:

  • Energy sensing: raises SIRT1 (sirtuin 1, a nutrient-sensing enzyme linked to aging) and activates AMPK (AMP-activated protein kinase, the cell’s energy-shortage sensor), favoring new mitochondria and fat use.
  • Antioxidant defense: switches on Nrf2 (a master regulator of antioxidant genes), raising protective enzymes such as HO-1 (heme oxygenase-1).
  • Inflammation and immunity: blocks NF-κB (a central inflammation switch) and Syk (spleen tyrosine kinase, an immune-cell signaling enzyme).
  • Metabolism: slows fat-cell formation, promotes muscle glucose uptake and inhibits α-glucosidase (a starch-digesting gut enzyme).

A competing reading is that benefits are dose-dependent stress responses: the catechol can oxidize into a reactive o-quinone (a damaging oxidized form) (a 2018 review by Bolton et al.), piceatannol inhibits mitochondrial ATP synthase (the enzyme producing cellular energy) (Zheng & Ramirez, 1999), and most effects require concentrations above those reached orally.

Pharmacology: Selectivity is low (multi-target). In rats, oral bioavailability is poor, plasma half-life is short while urinary terminal half-life is about 20 hours, and tissue distribution is wide (Roupe et al., 2006). Metabolism is mainly conjugation (glucuronidation and sulfation, which tag it for excretion) and methylation by COMT (catechol-O-methyltransferase, an enzyme inactivating catechols) into active isorhapontigenin and rhapontigenin, with little CYP (cytochrome P450, liver drug-metabolizing enzymes) involvement (Dai et al., 2020).

Historical Context & Evolution

Piceatannol takes its name from Picea (spruce), whose bark contains astringin, its sugar-bound form. It had no original medical use: in 1984 it was isolated as the anti-leukemia principle of Euphorbia lagascae seeds (Ferrigni et al., 1984), and through the 1990s it served mainly as a laboratory tool, a Syk-selective kinase inhibitor used to block signaling in mast cells (allergy-triggering immune cells) (Oliver et al., 1994).

Its path toward health optimization began in 2002, when researchers showed that CYP1B1 (a cytochrome enzyme abundant in tumors) converts resveratrol into piceatannol (Potter et al., 2002), suggesting it might mediate some resveratrol effects. As resveratrol’s longevity story met weak human results and poor bioavailability, attention shifted to more stable relatives. In 2010, scientists at Morinaga & Co., the Japanese confectionery company that now manufactures piceatannol-rich passion fruit seed extract, reported that the seeds are an abundant source (Matsui et al., 2010). Company-funded human trials followed from 2017, reporting skin and metabolic effects (Maruki-Uchida et al., 2018).

Independent research then broadened the picture in both directions: worm lifespan extension in 2017 and reduced markers of senescent (aged, non-dividing) cells in mice in 2026 strengthened the longevity rationale, while a 2025 university-run human trial without company authors, reported in two papers, found no change in fat metabolism or artery function. Piceatannol’s standing has therefore moved from laboratory reagent to candidate supplement, with its human case still open rather than confirmed or refuted.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no human clinical endpoint or validated clinical surrogate has been replicated in more than one independent placebo-controlled trial.

Medium 🟩 🟩

Skin Hydration & Wrinkle Appearance ⭕️ Not Central to Health & Longevity

In a randomized controlled trial of 82 Japanese women with dry skin, 10 mg/day for 8 weeks raised facial skin water content and improved crow’s-feet wrinkle grades versus placebo (Seto et al., 2026). An earlier 32-woman trial at 5 mg/day showed within-group hydration gains, with a placebo difference only in the driest-skin subgroup (Maruki-Uchida et al., 2018). Proposed mechanisms are collagen and hyaluronic acid support. Both trials were funded and staffed by Morinaga & Co. The effect bears on skin appearance and comfort rather than disease risk or lifespan.

Magnitude: After 8 weeks at 10 mg/day in women with dry skin, facial stratum corneum (outermost skin layer) hydration rose 24.9 µS (microsiemens) more than placebo on one instrument and 4.3 arbitrary units more on a second, and crow’s-feet grade (0–7 scale) fell 0.076 points more than placebo.

Low 🟩

Insulin Sensitivity

In an 8-week randomized trial of 39 adults co-authored by Morinaga & Co., 20 mg/day lowered fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance, a fasting insulin-glucose index) only in overweight men, five per arm (Kitada et al., 2017). Lean men and all women showed no effect.

Magnitude: In overweight men, HOMA-IR changed −17.2% with piceatannol versus +31.4% with placebo, and fasting insulin fell from 8.3 to 6.7 µU/mL.

Blood Pressure & Resting Heart Rate ⚠️ Conflicted

In the same trial, overweight men on piceatannol had lower blood pressure and heart rate; other subgroups showed no change (Kitada et al., 2017). An independent 7-day placebo-controlled trial in eight healthy men found no effect at 10 mg/day (Kasai et al., 2025). Net reading: an unreplicated subgroup signal.

Magnitude: In the five overweight men on piceatannol, systolic pressure fell from 131.4 to 120.8 mmHg, diastolic from 85.6 to 77.0 mmHg and heart rate from 67.6 to 59.0 beats/min over 8 weeks.

Reduced Fatigue ⚠️ Conflicted

In the 2018 Morinaga-funded skin trial, women taking 5 mg/day reported less fatigue on questionnaires than placebo (Maruki-Uchida et al., 2018). The 2017 trial at 20 mg/day found no change on a validated mood scale that includes fatigue. Net reading: an unreplicated secondary-outcome signal.

Magnitude: After 8 weeks at 5 mg/day in women with dry skin, the change in 100 mm visual-analogue fatigue ratings was +0.69 with piceatannol versus −0.54 with placebo, a difference of about 1.2 units in favor of piceatannol (16 women per group).

Fat Metabolism & Body Composition ⚠️ Conflicted

Unindexed Morinaga trials reported greater fat oxidation (cited in a 2024 Morinaga paper); a Sabinsa-funded multi-stilbene Cyperus rotundus extract reduced weight (Majeed et al., 2025). An independent trial found unchanged fat oxidation (Kasai et al., 2025); an 8-week trial found unchanged weight. Net reading: no reliable piceatannol fat-loss effect exists.

Magnitude: No difference in respiratory exchange ratio (a breath-gas index of fat versus carbohydrate burning), free fatty acids or ketones at 10 mg/day for 7 days, and no change in body weight or visceral fat at 20 mg/day for 8 weeks; these trials report no effect figure beyond non-significant differences.

Speculative 🟨

Systemic Inflammation & Oxidative Stress ⚠️ Conflicted

Cell and animal studies show anti-inflammatory and antioxidant activity, but 8 weeks at 20 mg/day left human inflammation and oxidative stress markers unchanged (Kitada et al., 2017). Net reading: support is preclinical only.

Vascular Function ⚠️ Conflicted

Piceatannol relaxes animal arteries via nitric oxide and prostacyclin (a vessel-relaxing signal) (a 2021 review), but human trials in 2017 and 2025 found unchanged flow-mediated dilation (ultrasound artery-relaxation test). Net reading: support is animal-only.

Lifespan Extension

In worms, 50–100 µM piceatannol extended lifespan and stress resistance through DAF-16 (the worm version of FOXO, longevity-linked gene regulators) (Shen et al., 2017). No mammalian lifespan study exists; basis is worm data only.

Senescent-Cell Reduction

In irradiated mice, oral piceatannol reduced senescent cells, their inflammatory secretions, and heart and kidney fibrosis (tissue scarring), improving coordination and memory (Ambrosino et al., 2026). Basis is animal data only.

Blood SIRT1 Upregulation ⚠️ Conflicted

A 302-person Morinaga trial at 100 mg/day raised whole-blood SIRT1 at 1 week, not 2 (Tanaka et al., 2024); a 2017 trial at 20 mg/day found none. Net reading: inconsistent across doses; unvalidated biomarker.

Neuroprotection

In aging mice, piceatannol reduced behavioral and neurological deficits through Nrf2 activation (Zhang et al., 2018). Basis is animal and cell data only; no human cognitive outcomes exist.

Anticancer Activity

Piceatannol inhibits growth of many cancer cell lines and animal tumors by triggering cell death and blocking growth signaling (a 2020 review by Banik et al.). No human cancer data exist; basis is preclinical.

Benefit-Modifying Factors

  • COMT genetics: COMT converts piceatannol into isorhapontigenin and rhapontigenin; the common low-activity Val158Met variant may shift the balance between parent compound and metabolites. Its effect on benefits is untested.
  • Baseline insulin and weight: Glucose and blood pressure improvements appeared only in overweight men with higher baseline insulin and triglycerides; lean, metabolically healthy adults showed no change.
  • Baseline skin hydration: Skin benefits appeared mainly in people with dry skin (Maruki-Uchida et al., 2018), and trials preferentially enrolled low-hydration participants, so gains in normally hydrated skin are unknown.
  • Sex: Metabolic effects appeared in overweight men but not overweight women, while blood SIRT1 induction appeared mainly in women, especially after menopause. Piceatannol’s weak estrogen-receptor activity may contribute.
  • Pre-existing conditions: Obesity, insulin resistance and elevated blood pressure are where early data suggest larger effects; no trial has enrolled people with diagnosed diabetes, heart disease or other chronic illness.
  • Age: Trials enrolled adults aged about 20–69; SIRT1 induction was significant in the 60–69 subgroup. No data exist beyond age 70, where lower conjugation capacity may alter exposure.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from five small, short controlled trials, none documenting a replicated excess of any adverse event.

Medium 🟥 🟥

No risk reaches Medium: no single controlled trial or observational dataset shows a statistically significant excess of any adverse event with piceatannol.

Low 🟥

Mild Urticaria

In a 302-person trial at 100 mg/day for 2 weeks, one transient urticaria (itchy raised welts) case per arm was judged product-related; gastric discomfort, diarrhea and headache were judged unrelated (Tanaka et al., 2024). Trials at 5–20 mg/day reported no serious adverse events.

Magnitude: Product-related urticaria in about 1 of 150 participants (≈0.7%) in each arm at 100 mg/day; no serious adverse events across roughly 470 trial participants.

Speculative 🟨

Immune Suppression

As a Syk inhibitor, piceatannol suppressed T-cell activation, proliferation and cytokine (immune signaling protein) production in mouse cells (Kim et al., 2015), raising theoretical infection or vaccine-response concerns. Basis is mechanistic only.

Pro-Oxidant & DNA-Damaging Metabolites

Its catechol can form an o-quinone; cell studies show cell-killing effects and some DNA damage (a 2021 review by Medrano-Padial et al.). Basis is cell data only; regulatory DNA-damage and animal toxicity testing are lacking.

Mitochondrial Energy Inhibition

Piceatannol inhibits mitochondrial ATP synthase in isolated-enzyme studies (Zheng & Ramirez, 1999), which could impair cellular energy at high concentrations. Oral doses likely yield far lower tissue levels; basis is mechanistic only.

Estrogen-Like Activity

Piceatannol acted as a phytoestrogen (plant-derived estrogen-like compound) through GPER (a membrane estrogen receptor) in fat cells (Arisawa et al., 2023). Relevance to hormone-sensitive disease is unknown; basis is cell and animal data.

Excess Glucose Lowering

In a Morinaga study, piceatannol lowered blood glucose in diabetic mice (Uchida-Maruki et al., 2015), so combining it with glucose-lowering drugs could theoretically raise hypoglycemia (low blood sugar) risk. Basis is animal data only.

Risk-Modifying Factors

  • COMT and UGT genetics: Low-activity COMT (Met/Met) or UGT1A1 (a liver enzyme that tags bilirubin and drugs for excretion) variants, as in Gilbert syndrome (mildly raised bilirubin), could raise circulating parent piceatannol, amplifying any dose-dependent effects. Human data are absent.
  • Baseline glucose: People with low-normal fasting glucose, or on glucose-lowering drugs, are more exposed to additive glucose lowering; baseline fasting glucose and HbA1c (a 3-month blood sugar average) frame this risk.
  • Liver and kidney function: Clearance depends on liver conjugation; elevated ALT (alanine aminotransferase, a liver-cell enzyme) or reduced eGFR (estimated glomerular filtration rate, a kidney-function estimate) may increase exposure.
  • Sex and hormone status: Estrogen-receptor activity makes women with hormone-sensitive conditions or on hormone therapy a theoretically higher-risk group; no sex-specific adverse events were reported in trials.
  • Pre-existing conditions: Autoimmune disease on immunosuppressants (immune-dampening drugs), hormone-sensitive cancers, Parkinson’s disease on COMT-dependent therapy, and passion fruit or latex allergy (latex-fruit syndrome, cross-reactive fruit allergy) raise theoretical risk.
  • Age: Adults over 70 were not studied; multiple medications, reduced conjugation capacity and greater vulnerability to hypoglycemia raise relevance of cautious dosing at the older end of the target range.

Key Interactions & Contraindications

Prescription drugs:

  • Glucose-lowering drugs (metformin, glimepiride, insulin): Monitor. Additive glucose lowering seen in mice may cause hypoglycemia; fasting glucose checks during the first 4 weeks mitigate this.
  • COMT-dependent Parkinson’s therapy (levodopa/carbidopa, entacapone, opicapone): Caution. Piceatannol is a COMT substrate and inhibitor that could alter levodopa handling and symptom control; separating doses by at least 2 hours and tracking symptoms mitigates this.
  • Drugs cleared by UGT1A6/1A9 (mycophenolate mofetil, propofol, deferiprone): Caution. Piceatannol broadly inhibits UGT (UDP-glucuronosyltransferase, drug-conjugating liver enzymes) in laboratory tests, potentially raising drug levels and toxicity (Jiang et al., 2020); drug-level monitoring mitigates this.
  • Immunosuppressants and Syk inhibitors (tacrolimus, ciclosporin, fostamatinib): Caution. Additive immune suppression through Syk and T-cell inhibition could increase infection risk; avoiding the combination, or pausing piceatannol during active infections, mitigates this.
  • Anticoagulants and antiplatelets (blood-thinning drugs: warfarin, apixaban, clopidogrel): Monitor. Related stilbenes inhibit platelets, though piceatannol did not in one assay (Ko et al., 1999); consequence would be bleeding. INR (clotting-time test) checks with warfarin mitigate this.
  • Hormone therapies (tamoxifen, letrozole, estradiol): Caution. Estrogen-receptor activity could theoretically interfere with hormone-targeted cancer treatment or add to hormone replacement effects; avoiding use during endocrine cancer therapy (hormone-blocking cancer treatment) mitigates this.
  • Antihypertensives (blood pressure drugs: amlodipine, lisinopril, losartan): Monitor. Blood pressure reductions in overweight men suggest possible additive lowering and dizziness; home blood pressure tracking mitigates this.

Over-the-counter medications:

  • Acetaminophen (paracetamol): Monitor. Acetaminophen is cleared partly by UGT1A6 and UGT1A9, which piceatannol inhibits in laboratory tests; shifted clearance could raise liver stress at high acetaminophen doses. Keeping acetaminophen within label limits mitigates this.
  • NSAIDs (non-steroidal anti-inflammatory drugs: aspirin, ibuprofen, naproxen): Monitor. Theoretical additive antiplatelet effect could increase bruising or gastrointestinal bleeding; attention to unusual bruising or dark stools mitigates this.

Supplements:

  • Resveratrol and pterostilbene: Monitor. Resveratrol is partly converted to piceatannol by CYP1B1, and all three share conjugation pathways, so stacking raises total stilbene exposure and any dose-dependent pro-oxidant effects; counting the combined dose mitigates this.
  • Green tea catechins (EGCG, epigallocatechin gallate) and quercetin: Monitor. These are also COMT and UGT substrates and may compete with piceatannol, raising levels of each and amplifying their dose-dependent pro-oxidant effects; spacing doses several hours apart mitigates this.
  • Berberine, chromium, cinnamon extract: Monitor. Additive glucose lowering could cause hypoglycemia, especially alongside medication; fasting glucose checks mitigate this.
  • Fish oil, ginkgo, high-dose vitamin E: Monitor. Theoretical additive bleeding tendency with these platelet-affecting supplements; pausing all before surgery mitigates this.
  • Magnesium, beetroot nitrate, garlic extract: Monitor. Additive blood pressure lowering could cause dizziness; home blood pressure readings mitigate this.

Other interventions:

  • Endurance or strength training: Monitor. Antioxidant polyphenols may blunt training adaptations; consequence would be smaller fitness gains. Dosing away from training sessions is a commonly used mitigation.
  • Elective surgery: Caution. Theoretical bleeding and glucose effects; a 14-day pause before procedures is a common precaution for polyphenol supplements.

Populations who should avoid Piceatannol:

  • Pregnant or breastfeeding women (no safety data)
  • Children and adolescents under 18 years
  • People with active hormone-sensitive cancer (estrogen-receptor-positive breast, endometrial or ovarian cancer) or on endocrine therapy
  • Organ-transplant recipients and others on systemic immunosuppressants
  • People with known passion fruit, grape or latex allergy (for passion fruit seed extracts)
  • Moderate-to-severe liver impairment (Child-Pugh Class B or C, a liver-disease severity score) or advanced kidney disease (eGFR <30 mL/min/1.73 m²)
  • Anyone within 14 days before elective surgery

Risk Mitigation Strategies

  • Trial-tested dosing: Doses of 5–20 mg/day for up to 8 weeks, and 100 mg/day for only 2 weeks, have been studied; staying within 10–20 mg/day limits exposure to untested dose-dependent pro-oxidant and mitochondrial effects.
  • Glucose checks with diabetes medication: Weekly fasting glucose for the first 4 weeks, with readings below 70 mg/dL as the alert threshold, mitigates hypoglycemia when combined with glucose-lowering drugs or supplements.
  • Immune-suppression precautions: Avoiding piceatannol alongside immunosuppressants and pausing it during active infections limits the Syk- and T-cell-mediated immune suppression seen in mouse cell studies; no human immune data exist to define a pause length.
  • Hormone-status screening: Checking for estrogen-receptor-positive breast, endometrial or ovarian cancer and current hormone therapy before starting, and avoiding use during endocrine cancer therapy, limits exposure to piceatannol’s estrogen-like GPER activity.
  • Stilbene dose accounting: Summing resveratrol, pterostilbene and piceatannol intake limits cumulative catechol and conjugation load, reducing pro-oxidant and interaction risk from stacking.
  • Low-dose tolerance run-in: Starting at 5 mg/day for 3–7 days before a full dose identifies urticaria or allergic reactions early, particularly in people with latex or fruit allergies.
  • Laboratory safety check: Baseline and 3-month ALT, AST (aspartate aminotransferase, a liver and muscle enzyme) and eGFR detect liver or kidney strain, given absent long-term human toxicity data.
  • Pre-surgical pause: Stopping 14 days before elective procedures removes theoretical bleeding and glucose-lowering effects around surgery.
  • Levodopa dose separation: Taking piceatannol at least 2 hours apart from levodopa and tracking symptom control mitigates COMT-related interaction.

Therapeutic Protocol

  • Metabolic protocol: 20 mg/day piceatannol in capsules for 8 weeks, the regimen behind the insulin-sensitivity and blood pressure findings in overweight men (Kitada et al., 2017, with Morinaga & Co.).
  • Skin protocol: 5–10 mg/day as passion fruit seed extract for 8 weeks, the regimen used in both Morinaga-funded skin trials (Maruki-Uchida et al., 2018; Seto et al., 2026).
  • Higher-dose short course: 100 mg/day, split into three servings, for 2 weeks; used only in the SIRT1 biomarker trial, with no longer-term data.
  • Competing approaches: Isolated passion fruit seed extract (Morinaga & Co.), multi-ingredient stem-cell formulas pairing piceatannol with resveratrol and garcinol (Life Extension with Insilico Medicine), resveratrol as a precursor, or food sources; none is established as superior.
  • Time of day: Both skin trials dosed in the evening, the 2026 trial between dinner and bedtime and the 2018 trial before bed; other trials used twice- or thrice-daily dosing. No study compares morning and evening dosing.
  • Half-life: Human half-life has not been published in indexed journals; in rats, plasma half-life is a few hours, while urinary terminal half-life is about 20 hours, with active methylated metabolites circulating longer.
  • Single vs split dosing: The 10 mg/day skin trial used once-daily dosing, the 20 mg/day metabolic trial two daily doses, and the 100 mg/day trial three servings. Short plasma half-life offers a theoretical rationale for splitting higher doses.
  • Genetic polymorphisms: No dosing data exist for COMT or UGT1A1 variants; low-activity carriers may reach higher parent-compound levels, making lower starting doses a conservative option.
  • Sex: Metabolic signals appeared in men, skin trials enrolled only women, and SIRT1 induction was stronger in women; no sex-specific dosing has been tested.
  • Age: Trials covered ages 20–69; adults over 70 have no dosing data, and the lower 5–10 mg/day range reflects the most conservative tested exposure.
  • Baseline biomarkers: Elevated fasting insulin, HOMA-IR or triglycerides in overweight men, and low skin hydration, marked responders; normal baseline values predicted no measurable change.
  • Pre-existing conditions: Overweight and insulin resistance are the studied responder states; people with diagnosed diabetes, cardiovascular disease or autoimmune disease were excluded from trials.

Discontinuation & Cycling

  • Short-term vs lifelong: Marketed as an ongoing longevity supplement, but human trials lasted only 1–8 weeks, so use beyond 2 months is unstudied for both benefit and safety.
  • Withdrawal effects: None reported; piceatannol has no known dependence or rebound mechanism.
  • Tapering: No tapering protocol is needed; people on glucose-lowering or blood pressure drugs may see small upward shifts after stopping, which routine monitoring captures.
  • Cycling: No evidence shows cycling maintains efficacy. Blood SIRT1 induction faded by week 2 at 100 mg/day (Tanaka et al., 2024), which some interpret as adaptation; 8-weeks-on, 4-weeks-off schedules mirror trial durations but are untested.
  • Reassessment point: Comparing skin, glucose and blood pressure measures against baseline after 8–12 weeks, the longest tested duration, defines whether continuation is showing any measurable effect.

Sourcing and Quality

  • Passion fruit seed extract: The most studied form, derived from Passiflora edulis seeds and produced mainly by Morinaga & Co. in Japan; all positive single-ingredient piceatannol trials used this source.
  • Standardization: Labels stating milligrams of piceatannol per serving, not only extract weight, allow matching to trial doses of 5–20 mg/day.
  • Third-party testing: No USP (United States Pharmacopeia) or NSF (NSF International) certified piceatannol products are known; a certificate of analysis with HPLC (high-performance liquid chromatography) purity, heavy metals and microbial testing is the available quality check.
  • Research-grade chemical: Synthetic piceatannol sold by laboratory suppliers is labeled for research use, not manufactured to food or supplement standards, and lacks consumer quality controls.
  • Stability and formulation: The catechol structure oxidizes readily, so light- and air-protected packaging matters; complexing with α-cyclodextrin (a ring-shaped sugar carrier) improved absorption in a Morinaga rat study (Inagaki et al., 2016).
  • Brands: Morinaga’s extract is sold mainly in Japanese functional foods; in the United States, Life Extension markets a formula combining piceatannol with resveratrol and garcinol.

Practical Considerations

  • Time to effect: Skin hydration changes appeared at 4–8 weeks, metabolic changes at 8 weeks, and blood SIRT1 changes within 1 week; no benefit has been measured beyond 8 weeks.
  • Common pitfalls: Assuming resveratrol results transfer to piceatannol, dosing by extract weight rather than piceatannol content, stacking multiple stilbenes, buying research chemicals, and expecting fat loss that independent trials did not find.
  • Regulatory status: In the United States it is sold as a dietary supplement ingredient with no FDA (US Food and Drug Administration) approved medical use; in Japan it is used in functional foods; no regulator has evaluated a health claim.
  • Food sources: Grapes, blueberries and white tea provide far less than trial doses; passion fruit seeds are the richest known food source, though typical fruit intake does not deliver standardized amounts.
  • Cost and accessibility: Not exceptionally expensive, but standardized products are harder to find outside Japan.

Interaction with Foundational Habits

  • Sleep: No direct interaction measured. The 2026 skin trial dosed between dinner and bedtime without reported sleep complaints, and piceatannol has no stimulant action; no study has assessed sleep quality or duration.
  • Nutrition: Potentiating in theory. α-glucosidase inhibition may blunt post-meal glucose rises, and calorie restriction also raises SIRT1, overlapping its proposed mechanism. Polyphenol-rich diets add stilbenes from grapes and berries; trials used capsules, tablets or drinks at varying times of day.
  • Exercise: None measured, with theoretical blunting. One independent 7-day trial at 10 mg/day found no change in fat oxidation or hormone responses or artery responses to cycling; antioxidant polyphenols may dampen training adaptations, so dosing away from workouts is a common practice.
  • Stress management: None measured. Cortisol responses to exercise were unchanged at 10 mg/day (Kasai et al., 2025), and 8 weeks at 20 mg/day did not change mood scores on the Profile of Mood States questionnaire (Kitada et al., 2017); no direct stress-axis effect has been shown.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes a personal reference for the markers piceatannol might influence: fasting glucose, fasting insulin with HOMA-IR, HbA1c, ALT, AST, eGFR and hs-CRP (high-sensitivity C-reactive protein, a blood inflammation marker), plus a week of morning home blood pressure and resting heart rate readings. For skin goals, standardized facial photographs and a note of seasonal conditions provide a comparison point, since humidity changes affect skin hydration.

Ongoing monitoring follows this cadence: at 4 weeks (fasting glucose and home blood pressure, especially with glucose-lowering or blood pressure drugs), at 8–12 weeks (repeat of the full baseline panel to judge response), then every 6–12 months during continued use. Success is defined as a measurable improvement from the individual’s own baseline, such as lower HOMA-IR or blood pressure, or improved skin hydration, without adverse changes in liver or kidney markers.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 75–90 mg/dL Detects glucose lowering or hypoglycemia Conventional range 70–99 mg/dL; 8–12 hour fast; morning draw
Fasting insulin 2–6 µIU/mL Tracks insulin sensitivity response Conventional range about 2–25 µIU/mL; draw with fasting glucose
HOMA-IR Below 1.0 Primary outcome in the metabolic trial Conventional cutoff below 2.5; calculated as glucose (mg/dL) × insulin ÷ 405
HbA1c 4.8–5.4% 3-month glucose average Conventional normal below 5.7%; no fasting required; pair with fasting glucose
Home blood pressure Below 120/80 mmHg Tracks reported blood pressure lowering Seated morning readings averaged over 7 days; same arm and time
Resting heart rate 50–70 beats/min Tracks reported heart rate lowering Conventional range 60–100 beats/min; measured on waking before caffeine; average over 7 days
ALT and AST Below 25 U/L each Liver safety Conventional upper limit about 40–55 U/L; avoid strenuous exercise 48 hours before testing
eGFR Above 90 mL/min/1.73 m² Kidney clearance of conjugates Conventional normal above 60; hydration affects creatinine; pair with cystatin C (an alternative kidney-filtration marker)
hs-CRP Below 1.0 mg/L Systemic inflammation Conventional low-risk below 3.0 mg/L; repeat if above 10 mg/L (acute illness)
Skin hydration No established target; track change from own baseline Skin outcome with the most trial support Corneometer or similar device at dermatology clinics; measure in the same season and room conditions

Qualitative markers:

  • Skin dryness, texture and fine-wrinkle appearance
  • Daytime energy and fatigue
  • Digestive tolerance (gastric discomfort, diarrhea)
  • Skin reactions such as urticaria or itching
  • Unusual bruising or bleeding
  • Dizziness or light-headedness on standing

Emerging Research

  • Terminated inflammatory-age supplement trial: NCT04983017 randomized 781 adults to immune-type-specific supplement blends, some containing piceatannol, to lower iAge (an immune-based inflammatory-age score); it was terminated because blends did not differ from placebo, weakening the case for low-dose multi-ingredient stacks.
  • Intravenous piceatannol derivative: NCT06127381 is a Phase 1 open-label dose-escalation study in 25 healthy volunteers of glycolic-acid-tetrasubstituted piceatannol (TGKP), developed for acute respiratory distress syndrome (sudden severe lung failure); status unknown, but it may yield the first registered human safety and pharmacokinetic (absorption and clearance) data for a piceatannol-based drug.
  • Ongoing trials: No ongoing registered trial of oral piceatannol for aging, metabolic or skin outcomes was found on ClinicalTrials.gov as of September 24, 2026.
  • Senotherapeutic (senescent-cell-targeting) translation: Ambrosino et al., 2026 reported reduced senescent cells and inflammatory secretions in a mouse model of mild aging at a human-translatable oral dose; human senescence-biomarker trials would test whether this transfers.
  • Independent replication: One independent 2025 trial by Kasai et al., reported in two papers, found no effect on fat metabolism (Kasai et al., 2025) or artery function (Kasai et al., 2025); longer independent trials could confirm or overturn the company-funded metabolic findings.
  • Brain and COMT biology: Dai et al., 2020 identified piceatannol as a COMT substrate and inhibitor converted to active metabolites, suggesting neurological applications and interaction questions that remain untested in people.
  • Drug-interaction mapping: Jiang et al., 2020 showed broad UGT inhibition in laboratory tests; human interaction studies would clarify whether this matters at supplement doses.

Conclusion

Piceatannol is a close chemical relative of resveratrol, richest in passion fruit seeds, that switches on cellular stress-defense and energy-sensing programs in laboratory and animal studies. For health-focused adults, its appeal lies in signs that it may slow features of aging in worms and mice, and in its better stability in the body compared with resveratrol.

The human evidence is thin. A handful of short, small trials report moister skin and fewer visible wrinkles in women with dry skin, and better blood glucose control, lower blood pressure and a slower heart rate in a very small group of overweight men. Other groups in the same trials, and an independent study in young men, showed no change in fat metabolism, blood vessel function, inflammation or body weight. Claims of longer life or fewer aging cells rest entirely on animal and cell research.

Short-term use appears well tolerated, with only occasional mild skin reactions. Longer-term safety is unknown, and laboratory studies raise open questions about immune dampening, weak estrogen-like activity, reactive breakdown products and effects on cellular energy, along with possible overlap with diabetes, Parkinson’s and hormone treatments.

Nearly all positive human trials were funded, staffed or co-authored by Morinaga, the Japanese company that manufactures the passion fruit seed extract, while the one trial run without company authors found no effect. For this audience, piceatannol remains an early-stage, largely laboratory-based longevity candidate whose skin effects have the most support and whose broader health effects are unproven.

Top - Benefits - Risks - Protocol